We are in a mental health crisis, and we need new, more effective therapies fast. Psychedelic drugs such as psilocybin, DMT, LSD, MDMA, and ketamine have...
In recent years, advancements in the field of psychedelic medicine have been gaining attention, and bringing with them their own concerns about sourcing...
Truffle Report has compiled a roundup of major psychedelic business news stories from the week of February 7-11, making it easier for you to access these...
What makes a work of art truly transcendent? Is it an exhibition of mastery, or an abundance of mystery? Is it the presence of genius, or...
Peyton Nyquvest is the CEO of Numinus, a Canadian publicly-traded company that is involved in psychedelic synthesis, research and treatment. Numinous recently...
This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the...
The firm has made meaningful strides in its early clinical runway as it gears up for government-funded studies. The post Awakn Life Sciences’ Revenue...
Breaking Convention in Exeter is the indie label equivalent to the corporadelic mega conventions taking over across the psychedelic realm, with equal emphasis...
-Mindbloom, the world’s largest provider of ketamine therapy, announced today a partnership with SHIFT, a tech-enabled management consulting firm, to...
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced upcoming event...